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SObjectives: Surveillance endoscopy has been recommended for patients with Barrett’s esophagus; however, re-
cent studies have questioned the importance owing to the new, lower, estimates of the rate of progression of Bar-
rett’s esophagus to cancer. The aim of the present study was to compare the tumor stage, survival, and frequency
of esophageal preservation in patients who presented with progression of Barrett’s esophagus within a surveil-
lance program versus those who presented with prevalent disease.
Methods: A retrospective chart review was performed of all patients treated for high-grade dysplasia or esoph-
ageal adenocarcinoma from 2005 to 2010. The surveillance group included patients who had had at least 1 en-
doscopy and biopsy confirming intestinal metaplasia (with or without low-grade dysplasia) 6 months or more
before the endoscopy showing progression.
Results: A total of 224 patients were included in the present study, 36 in the surveillance group and 188 in the
prevalence group. The surveillance patients had significantly earlier stage tumors (P<.0001) and were more
likely to undergo endoscopic therapy and to keep their esophagus (44% vs 11%, P<.0001) than were patients
with prevalent disease. Furthermore, the patients in the surveillance group were less likely to have lymph node
metastases and had better overall and disease-free survival. No patient with high-grade dysplasia or an intramu-
cosal tumor died of cancer.
Conclusions: Patients within a surveillance program for Barrett’s esophagus had better survival and were less
likely to have an esophagectomy than those who presented with prevalent disease. Treatment of intramucosal
cancer was curative, and improved survival with surveillance was not secondary to lead time bias. Surveillance
endoscopy remains important in patients with Barrett’s esophagus. (J Thorac Cardiovasc Surg 2013;146:31-7)Esophageal adenocarcinoma is 1 of the world’s deadliest
cancers, with a 15% overall 5-year survival rate. The major
risk factor for esophageal adenocarcinoma is Barrett’s
esophagus (BE). The development of adenocarcinoma
from BE is known to occur through a series of histologic
changes in the metaplastic epithelium, starting with dyspla-
sia and endingwith invasive cancer. Surveillance endoscopy
has been recommended for patients with BE to allow the de-
tection of progression and treatment at a curable stage of the
disease. However, several recent studies have suggested that
the risk of progression in patients with BE is lower than pre-
viously reported, have questioned the value of surveillance
endoscopy, and have promoted a laissez-faire attitude to-
ward BE.1,2 Concurrent with these reports have been
studies indicating that patients with BE and high-grade dys-
plasia (HGD) or intramucosal adenocarcinoma can often bee Departments of Surgerya and Pathology,b University of Southern California
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The Journal of Thoracic and Csuccessfully treated endoscopically, with preservation
of their esophagus.3,4 In contrast, esophagectomy, usually
combined with neoadjuvant chemoradiotherapy, is
required to treat patients with more advanced tumors. The
aim of the present study was to compare the tumor stage,
survival, and frequency of esophageal preservation
between patients who presented with progression of BE
within a surveillance program and those who presented
with prevalent disease outside of a surveillance program.
METHODS
Patients
We reviewed the records of all patients treated with endotherapy or
esophagectomy for HGD or esophageal adenocarcinoma by the thoracic
surgery division from 2005 to 2010. We selected 2005 for the start of the
study because, by that point, endoscopic therapy with both endoscopic re-
section and ablation was well established at our center. The patients were
considered to be under surveillance if they were aware of their diagnosis of
BE and had had at least 1 endoscopy and biopsy confirming intestinal meta-
plasia (with or without low-grade dysplasia) a minimumof 6 months before
the endoscopy showing disease progression to either HGD or invasive ad-
enocarcinoma (surveillance group). The surveillance group was compared
with patients found at index endoscopy to have either HGD or invasive ad-
enocarcinoma (prevalence group). The institutional review board of the
University of Southern California approved the study.
Endoscopic Therapy Versus Esophagectomy
Upper endoscopy was performed by the attending thoracic surgeon in
all patients before deciding on the type of therapy. Patients with HGD orardiovascular Surgery c Volume 146, Number 1 31
Abbreviations and Acronyms
BE ¼ Barrett’s esophagus
HGD ¼ high-grade dysplasia
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Sa biopsy diagnosis of adenocarcinoma, in whom Barrett’s mucosa was
completely flat without any nodules or lesions, were eligible for ablation
with radiofrequency energy using the Halo 360 or 90 device (BA^RRX
Medical, Covidien, Mansfield, Mass). In patients with HGD or a biopsy
finding showing adenocarcinoma, in whom Barrett’s mucosa showed an
ulcer or lesion of any type, endoscopic resection of the lesion was per-
formed to pathologically determine whether cancer was present and, if
so, the depth of invasion. Patients with tumors invasive beyond the muscu-
laris mucosa into the submucosa were not eligible for endoscopic therapy
or vagal-sparing esophagectomy. These patients were advised to undergo
esophagectomy with lymph node dissection, most commonly using an en
bloc technique. If the lesion was confirmed to be intramucosal by endo-
scopic resection, the patients were eligible for endoscopic therapy or
vagal-sparing esophagectomy. The decision between these options was de-
termined by patient preference, the degree of esophageal dysfunction, the
severity of reflux disease, the length of BE, and presence of multifocal
disease.5
Vagal-sparing esophagectomy removes the diseased esophagus but does
not remove the lymph nodes; thus, it is applicable only for patients with
HGD or intramucosal tumors. These patients have a low risk of lymph
node metastases.6 In patients who elected to undergo endoscopic therapy
for their disease, our preferred approach consisted of endoscopic resection
for any nodules within the Barrett segment, and radiofrequency ablation for
residual intestinal metaplasia, until BE was completely eradicated.5 Endos-
copy was performed 8 weeks after endotherapy. If any intestinal metaplasia
was still present, the patient underwent prompt reablation or additional en-
doscopic resection. This pattern was repeated until all the intestinal meta-
plasia was eradicated. Once the patient was rendered free of intestinal
metaplasia, surveillance endoscopies were done every 3 months for the first
year, every 6 months for the second year, and annually thereafter. Any re-
currence of intestinal metaplasia was treated with additional endoscopic
ablation or resection.
Staging
Patients with HGD or intramucosal cancer proven by endoscopic resec-
tion did not undergo routine positron emission tomography, computed to-
mography, or endoscopic ultrasonography. Patients with submucosal or
deeper tumors underwent routine endoscopic ultrasonography and com-
puted tomography-positron emission tomography, with additional staging
studies as indicated. Patients with evidence of stage N2 disease (3-6 in-
volved nodes) were typically offered neoadjuvant therapy. After therapy
completion, the patients underwent repeat staging studies and, in the ab-
sence of metastatic disease, were offered esophagectomy. Staging was re-
ported according to the 7th edition of the Cancer Staging Manual by the
American Joint Committee on Cancer.7
Statistical Analysis
Comparisons of proportions were performed using the Fisher exact test
or chi-square analysis. Survival estimates were calculated according to the
Kaplan-Meier method and compared using log-rank analysis.RESULTS
A total of 224 patients were treated with endotherapy
or esophagectomy for HGD or invasive esophageal32 The Journal of Thoracic and Cardiovascular Surgeadenocarcinoma during the 6-year study period: 36 in the
surveillance group and 188 in the prevalence group. The
characteristics, treatment, and tumor stage of patients in
the 2 groups are listed in Table 1. No significant differences
were found in age or gender; however, the patients in the
surveillance group had a significantly greater prevalence
and longer duration of reflux symptoms. All but 7 of the
36 surveillance patients had undergone surveillance else-
where and were referred to our center for evidence of dis-
ease progression. The surveillance interval ranged from 6
months to 4 years, and the median number of endoscopies
before the one showing progression was 3 in the surveil-
lance group. In contrast, most patients in the prevalence
group had not previously undergone endoscopy. Signifi-
cantly more patients had HGD or intramucosal adenocarci-
noma in the surveillance group (64%) compared with the
prevalence group (26%). More than two thirds of the pa-
tients in the surveillance group first received endoscopic
therapy compared with only 17% in the prevalent group.
Also, 44% of the surveillance group had successful endo-
therapy and kept their esophagus compared with 12% in
the prevalence group.
Esophagectomy was performed in 20 of the 36 patients
(56%) in the surveillance group. Of these 20 patients, 9
first received endotherapy and subsequently underwent
esophagectomy because the lesion was found to be inva-
sive into the submucosa on endoscopic resection (2 pa-
tients), multifocal intramucosal cancer was present
(5 patients), or patient preference or failed attempts at en-
dotherapy (2 patients). Almost one half of the esophagec-
tomies could be done with a vagal-sparing technique,
given the superficial disease in these patients. In contrast,
in the prevalence group, 166 of the 188 patients (88%)
underwent esophagectomy, and only 7% were eligible
for a vagal-sparing approach. In the prevalence group,
10 patients were initially treated with endotherapy but
underwent esophagectomy for invasion into the submu-
cosa on endoscopic resection (5 patients), multifocal in-
tramucosal cancer (1 patient), and patient preference or
failed attempts at endotherapy (4 patients). No patient
in the surveillance group received neoadjuvant therapy,
and 80% of those who underwent esophagectomy had
node-negative disease. In contrast, 32% of patients in
the prevalence group received neoadjuvant therapy, and,
after esophagectomy, 49% had involved lymph nodes,
with almost one fourth having 7 or more lymph node me-
tastases (N3 disease).
The 90-day mortality rate in the surveillance group was
0% compared with 1% in the prevalence group. The me-
dian, disease-free, and overall survival were significantly
better in the surveillance group (Figure 1). In the subgroup
of patients with HGD or intramucosal (T1a) lesions, no
cancer-related deaths had occurred in either group at a me-
dian follow-up of 22 months.ry c July 2013
TABLE 1. Patient characteristics, tumor stage, and treatment
Characteristic Surveillance group (n ¼ 36) Prevalence group (n ¼ 188) P value
Age (y)
Median 70 69 NS
IQR 64-81 60-77
Gender (n) NS
Male 33 166
Female 3 22
Lifetime prevalence of GERD symptoms 36/36 (100%) 119 (63%) <.0001
Duration of reflux symptoms (y) <.0001
Median 30 5
IQR 20-40 0-20
Indication for EGD NA
Dysphagia 91 (48%)
Anemia/GI bleed 27 (14%)
Pain (abdomen, chest) 17 (9%)
Other 53 (28%)
Endoscopy before HGD or EA diagnosis (n) NS
Median 3 0
IQR 2-5
Treatment
Endotherapy (resection  ablation) 25 (69%) 32 (17%) <.0001
Endotherapy only 16/36 (44%) 22/188 (11%) <.0001
Initial endotherapy, subsequent 9/36 (25%) 10/188 (5%) .0005
Esophagectomy <.0001
Esophagectomy as initial therapy 11 (31%) 156 (83%) <.0001
Esophagectomy type <.0001
Vagal-sparing 9 (45%) 12 (7%)
All other types 11 (55%) 154 (93%)
Neoadjuvant therapy 0 60 (32%) <.0001
Follow-up (mo) .04
Median 35 24
IQR 19-46 13-41
Pathologic T stage <.0001
ypT0 NA 12 (6%)
HGD 5 (14%) 8 (4%)
T1a 18 (50%) 41 (22%)
T1b 11 (31%) 15 (8%)
T2 2 (6%) 26 (14%)
T3 0 86 (46%)
Esophagectomy patients only 20 166
Pathologic N stage .04
N0 16 (80%) 84 (51%)
N1 (1-2 positive nodes) 3 (15%) 22 (13%)
N2 (3-6 positive nodes) 1 (5%) 23 (14%)
N3 (7 positive nodes) 0 37 (22%)
Overall survival (mo) 59 55 .01
3-Year disease-free survival* 15/17 (88%) 47/105 (45%) .0011
NS, Not significant; GERD, gastroesophageal reflux disease; IQR, interquartile range; EGD, esophagogastroduodenoscopy; NA, not applicable; GI, gastrointestinal; HGD, high-
grade dysplasia; EA, esophageal adenocarcinoma. *Patients who completed at least 3 years of follow-up.
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SDISCUSSION
The incidence of BE is increasing and has been estimated
to be present in 5.6% of the general population in the
United States.8,9 BE is the only known precursor lesion
for esophageal adenocarcinoma, the fastest increasing
cancer in America.10When BE progresses to cancer, it often
does so in an orderly fashion, starting with nondysplasticThe Journal of Thoracic and CBE and progressing to low-grade dysplasia, HGD, and,
finally, invasive adenocarcinoma. The recommendation
for surveillance endoscopy for patients with BE is predi-
cated on the concept that some patients with BE will de-
velop disease progression and the identification of
progression at a treatable or curable stage should improve
survival. No randomized controlled trials have beenardiovascular Surgery c Volume 146, Number 1 33
FIGURE 1. Kaplan-Meier curve showing overall survival in surveillance
and prevalence groups.
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Spublished to support this concept, but several retrospective
series have shown that compared with patients who present
with prevalent or nonsurveillance-detected cancer, those
who have their cancer identified within a surveillance pro-
gram have earlier stage tumors and better survival.11-13
The treatment of progression in these previous studies was
esophagectomy. In the present study, we confirmed the
finding that surveillance patients had earlier stage tumors
and improved survival compared with patients who
presented with prevalent cancer. HGD or intramucosal
cancer was the final pathologic stage in 64% of patients
in the surveillance group compared with 26% in the
prevalent group. These early-stage lesions are nearly always
curable, and in the present series, no patient died of cancer
after treatment for HGD or intramucosal cancer. These are
also the lesions amenable to endoscopic therapy, and the pa-
tients in the surveillance group were significantly more
likely to receive endoscopic resection and/or ablation and
to keep their esophagus than were patients in the prevalence
group. In the later years of the study, the frequency and suc-
cess of endoscopic therapy increased as we became more
comfortable with extended endoscopic resections using the
band technique and had better devices for ablation of resid-
ual BE.
Most patients in the surveillance group (29/36, 81%)
were referred to us once progression to HGD or invasive ad-
enocarcinoma was identified. In these 29 patients, the sur-
veillance interval was as long as 4 years and 45% had
tumors invasive into the submucosa or deeper whereas and
55% had lymph node metastases. Of this group, 14%
have died of cancer. In contrast, 7 patients developed pro-
gression during surveillance at our institution. Of these, 4
had intramucosal adenocarcinoma and 3 had HGD. None
of these 7 patients has died of cancer. Our policy has been
annual endoscopic surveillance for nondysplastic BE; thus,
all 7 of these patients were found with early-stage, curable
disease. Although our surveillance group was too small to
correlate tumor stage and survival with the surveillance in-
terval, it is logical that a shorter interval will maximize the
detection of earlier stage lesions and the potential for cure.urgeThe findings in our study have relevance to the ongoing
controversy regarding surveillance endoscopy for patients
with BE.14-16 The arguments against surveillance have
focused on the infrequency of disease progression, the
inaccuracy of the histologic diagnosis of dysplasia, that
most patients with adenocarcinoma present with prevalent
disease with no previous diagnosis of BE, the morbidity
and mortality of esophagectomy to treat disease
progression, and the cost of surveillance with repeated
endoscopy and biopsy.17 Given the cost and complexity of
clinical trials to evaluate surveillance for BE, a number of
studies have used a mathematical Markov model to explore
hypothetical cohorts of patients with BE in an attempt to de-
termine the cost-effectiveness of BE surveillance compared
with other accepted practices, such as mammography for
breast cancer and screening for colorectal cancer and organ
transplantation. In 1999, Provenzale and colleagues18 con-
cluded that surveillance every 5 years was the only viable
strategy to provide an incremental cost-effectiveness ratio
comparable with other accepted practices. In their model,
the risk of progression to cancer was 0.4% annually, treat-
ment of progression was esophagectomy, and the mortality
with esophagectomy was 9.5%.18 Another study using the
same Markov model, but with different values for some of
the variables, concluded that biannual surveillance yielded
an incremental cost-effectiveness ratio of $16,965 per
quality-adjusted life-year. This was more than screening
for colorectal cancer ($11,000) but less than erythropoietin
therapy for anemia in dialysis patients ($180,000). In that
analysis, the risk of progression to cancer was 0.5%, treat-
ment of progression was esophagectomy, and mortality
with esophagectomy was 3.5%.19
These Markov models are very sensitive to the variables
used for the analysis, including the rate of progression of BE
to cancer. Recently, 2 studies were published that indicated
that the rate of progression to cancer with BE was lower
than the previously accepted rate of 0.5% annually.1,2
The first of these studies, a population-based study from
Northern Ireland, found that the rate of progression to can-
cer was 0.16% annually.1 The second study used a pathol-
ogy registry that encompassed the entire population of
Denmark and reported a rate of progression of 0.12% annu-
ally.2 One problem in the study from Northern Ireland was
the inclusion of patients with a columnar-lined esophagus
without intestinal metaplasia. Although debated, most evi-
dence has suggested that intestinal metaplasia is the hall-
mark of a mucosa at risk of progression to cancer.20,21
When the authors of the study from Northern Ireland
restricted their analysis to those with intestinal
metaplasia, the rate of progression to cancer increased to
0.27%, and when progression to HGD was included, the
rate was 0.38% annually.1 The study from Denmark in-
cluded only patients with intestinal metaplasia; however,
cancer at the gastroesophageal junction was not included.2ry c July 2013
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that many, if not most, patients had short segments.2 Thus,
exclusion of gastroesophageal junction cancer almost cer-
tainly led to a significant underappreciation of the true
risk of progression.2 Furthermore, both studies excluded
all patients who developed cancer within the first year of
the diagnosis of BE. The inclusion of these patients would
have significantly increased the risk of progression (up to
0.29% in the Denmark study). Any discussion about
surveillance must include these patients because, if they
were not surveyed, they would have presented with preva-
lent cancer at some point after their diagnosis of BE.
Although the incidence of progression to cancer is one of
the key variables in a Markov model of BE surveillance,
other important variables include the type and cost of treat-
ment for patients with progression and the morbidity and
mortality associated with the treatment. All the published
Markov analyses for BE surveillance used esophagectomy
as the treatment for progression. In the decade since these
studies were published, much has changed in the therapy
for BE with progression during surveillance. One of the
most significant changes has been the introduction of endo-
scopic therapy for HGD and intramucosal adenocarcinoma.
In the present study, we have shown for the first time that
patients found to have progression within a surveillance
program are significantly more likely to be able to be treated
with endoscopic resection and ablation than patients who
present with prevalent cancer. Thus, nearly one half of the
surveillance patients kept their esophagus. We have previ-
ously shown that although survival is similar, the morbidity
with endoscopic therapy is significantly less than that with
esophagectomy.3 Furthermore, survival is excellent with
endotherapy or esophagectomy for early-stage disease.
None of the patients treated for HGD or intramucosal ade-
nocarcinoma in the present series died of cancer. Also, long-
term cure with esophagectomy or endotherapy for patients
with intramucosal adenocarcinoma has been shown in other
series.3,22,23 Cure with resection alone in these patients
refutes previous arguments that lead time bias is the only
reason patients undergoing surveillance appear to have
improved survival compared with nonsurveyed patients
and that esophageal adenocarcinoma is a systemic disease
at diagnosis.15
In the decade since the publication of these Markov
models, esophagectomy has also changed and improved.
Although mortality rates of 9.5% and 3.5% were used in
the cited studies,1,2 no 90-day mortality after esophagec-
tomy occurred in patients with progression during surveil-
lance in the present study, and it was only 1% for patients
with prevalent cancer. In those patients with only HGD or
intramucosal adenocarcinoma, no mortality occurred after
esophagectomy in either group, similar to other reports of
patients with these early lesions.24,25 In the present series,
19 patients underwent esophagectomy (10% of theThe Journal of Thoracic and Cesophagectomies) as a minimally invasive procedure.
Benefits, such as reduced morbidity, shorter hospital stay,
and faster recovery, could be present for these
patients.26,27 Furthermore, almost one half of the
esophagectomies in the surveillance group used a vagal-
sparing technique. Vagal-sparing esophagectomy is appli-
cable only for patients with HGD or intramucosal tumors,
with a minimal risk of lymph node metastases, and is asso-
ciated with reduced short- and long-term complications, in-
cluding perioperative infections and postvagotomy
dumping and diarrhea.22 The advantage of vagal-sparing
esophagectomy over endoscopic therapy is that it is typi-
cally a ‘‘one-shot’’ treatment, without the need for repeat
procedures, and eliminates the need for continued surveil-
lance because of the risk of persistent or recurrent local dis-
ease in the esophagus.28
In the present study, we also showed that patients with
prevalent cancer were significantly more likely to be treated
with neoadjuvant therapy, to have lymph node metastases,
and to die of cancer. Given all these factors, it is inappropri-
ate to assume that Markov models of surveillance, if re-
peated, would show worse cost-effectiveness than before
solely because of the recently published lower estimates
of the progression rates for BE. New studies need to include
the cost of chemotherapy and radiotherapy, the cost of endo-
therapy versus esophagectomy, and the improved modern
outcomes with these therapies in the Markov model. In ad-
dition, new modalities for surveillance and new methods to
detect dysplasia, including technology such as optical co-
herence tomography, might make surveillance less costly
and more reliable. Thus, the debate over surveillance for pa-
tients with BE is far from settled, and conclusions such as
those in the recent study from Denmark that ‘‘the risk of
esophageal adenocarcinoma among patients with Barrett’s
is so minor that in the absence of dysplasia, routine surveil-
lance of such patients is of doubtful value’’ are premature
and unfounded.2
The issue of screening for BE is even more controversial
than that of surveillance for known BE. Although 16% of
the patients treated during our 6-year study period had
surveillance-detected lesions, the unfortunate reality is
that 84% presented with prevalent disease and no previous
diagnosis of BE. Most had never had an endoscopy. This re-
flects the often-prompt institution of proton pump inhibitors
by primary care physicians and gastroenterologists, without
any additional evaluation beyond symptom assessment.
However, it also reflects that many patients who present
with a prevalent cancer never had significant reflux symp-
toms. This is a major issue in regard to screening. If screen-
ing endoscopy were recommended only for white men with
long-standing heartburn or regurgitation symptoms, it
would miss a large portion of the at-risk population. In
our study, that was a small group among those with preva-
lent cancer. Thus, to be effective, screening likely wouldardiovascular Surgery c Volume 146, Number 1 35
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50 years, at the same time as a screening colonoscopy. An-
other issue, in regard to screening, is that 6 patients with
prevalent cancer had undergone previous endoscopy within
5 years of the one that showed HGD or invasive adenocar-
cinoma. Disturbingly, in 3 patients, the previous endoscopy
was within 1 year of the diagnosis. Typically, either erosive
esophagitis or a normal esophagus was seen, but no biopsies
were done. All these endoscopies were performed at outside
facilities and reinforce the importance of routine biopsies at
the gastroesophageal junction and systematically within
a columnar-lined esophagus, with particular focus on any
lesions or nodules in the columnar mucosa. Perhaps new,
nonendoscopic screening techniques, such as the cyto-
sponge, developed by Lao-Sirieix and Fitzgerald,29 that
uses immunohistochemical biomarkers rather than cytology
to identify BE within a specimen, will allow cost-effective
and reliable screening within a broad population.
Our study had important limitations. It was a single-
institutional experience, and the numbers of patients, partic-
ularly in the surveillance group, were relatively small.
However, as a regional referral center for gastroesophageal
reflux disease, BE, and adenocarcinoma, we have no reason
to believe that any type of referral bias existed, either for the
surveillance-detected or prevalent lesions. Because most of
the patients in each group were referred with their disease,
we had to arbitrarily definewhat constituted surveillance for
the purposes of our study. We decided that the fairest defi-
nition for a surveillance patient would be a patient who
was aware they had BE and had had at least one endoscopy
showing BE, with at most low-grade dysplasia, a minimum
of 6 months before the endoscopy showing HGD or invasive
adenocarcinoma. It would have been ideal if most of the pa-
tients with progression had come from within our own co-
hort of patients with BE undergoing standardized, yearly
endoscopic surveillance. However, most of our patients
with BE undergoing surveillance had had an antireflux pro-
cedure, and it is possible that the risk of progression in these
patients is reduced. The effect of an antireflux procedure on
the risk of progression in BE remains controversial and was
outside the scope of the present study.30,31 Additional
limitations include that we did not know the denominator
of all patients with BE and/or adenocarcinoma evaluated
at our center from which to give a frame of reference for
the surveillance and prevalence groups included in the
present study. Furthermore, there likely were patients with
prevalent cancer who developed progression during
neoadjuvant therapy and never underwent esophagectomy.
These patients were not included in the present analysis,
and neither were patients who presented with prevalent
cancer and metastatic disease and underwent definitive
chemoradiotherapy or palliative interventions. The
inclusion of these patients undoubtedly would have
further separated the surveillance and prevalence groups.36 The Journal of Thoracic and Cardiovascular SurgeDespite these limitations, clear differences were seen
between the groups and should encourage additional
evaluation of the role of surveillance endoscopy and,
perhaps, screening for BE.
CONCLUSIONS
Most patients with esophageal adenocarcinoma pre-
sented with prevalent disease with no previous diagnosis
of BE. The majority of these patients had locally advanced
disease and required esophagectomy, often with the addi-
tion of neoadjuvant chemoradiotherapy, in an attempt to
cure the disease. In contrast, patients with disease progres-
sion within a BE surveillance program had earlier stage
tumors, and most were treated with endoscopic resection
and/or ablation. Significantly fewer patients in the surveil-
lance group required esophagectomy, and the survival in
this group was significantly better than that of patients
with prevalent disease. These findings should encourage
continued surveillance in patients with BE and perhaps con-
sideration of cost-effective mechanisms to screen at-risk
populations for the presence of BE.
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